NCT05804032 2026-02-18
Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma
University of Heidelberg Medical Center
Phase 3 Completed
Clinical Trials
6 trialsNCT05573802 2023-10-24
A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma
Hellenic Society of Hematology
Phase 1/2 Recruiting
NCT05147493 2022-03-29
A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment
Hellenic Society of Hematology
Phase 2 Unknown
NCT01002755 2019-05-07
Lenalidomide and Ofatumumab in Treating Participants With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02155634 2018-04-10
Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma
Celgene
Phase 3 Withdrawn
NCT00525447 2014-10-09
Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple Myeloma
Seagen Inc.
Phase 1 Completed